Stay updated on Biosimilar PCSK9 Inhibitors Clinical Trial

Sign up to get notified when there's something new on the Biosimilar PCSK9 Inhibitors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Biosimilar PCSK9 Inhibitors Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    6%
    Check dated 2025-02-10T09:25:12.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.3%
    Check dated 2025-02-03T05:26:14.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.0 to v2.14.1.
    Difference
    0.3%
    Check dated 2025-01-19T19:49:38.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    1.0%
    Check dated 2025-01-12T16:56:19.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The website has been updated from version v2.13.2 to v2.13.3.
    Difference
    0.3%
    Check dated 2024-12-14T12:21:44.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The website has been updated from version 2.12.2 to 2.13.2, indicating a new release with potential improvements or features.
    Difference
    0.3%
    Check dated 2024-12-07T10:31:15.000Z thumbnail image

Stay in the know with updates to Biosimilar PCSK9 Inhibitors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Biosimilar PCSK9 Inhibitors Clinical Trial page.